Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

NCT ID	NCT02446600
Title	Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Recruitment	Active, not recruiting
Gender	female
Phase	Phase III
Variant Requirements	No
Sponsors	National Cancer Institute (NCI)
Indications	ovarian cancer fallopian tube cancer peritoneum cancer fallopian tube serous adenocarcinoma peritoneal carcinoma endometrioid ovary carcinoma peritoneal serous adenocarcinoma fallopian tube clear cell adenocarcinoma ovarian serous carcinoma ovarian clear cell carcinoma fallopian tube endometrioid adenocarcinoma
Therapies	Cediranib + Olaparib Olaparib Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal-doxorubicin
Age Groups:	adult \| senior
Covered Countries	USA \| CAN